日韩av激情在线观看-又色又爽又黄的视频软件app-特黄特色三级在线观看-国内揄拍国内精品少妇国语

我們的服務(wù)

作為中國(guó)第三方檢測(cè)與認(rèn)證服務(wù)的開(kāi)拓者和領(lǐng)先者，CTI華測(cè)檢測(cè)為全球客戶提供一站式檢驗(yàn)、測(cè)試、校準(zhǔn)、認(rèn)證及技術(shù)服務(wù)。
行業(yè)解決方案

服務(wù)能力已全面覆蓋到紡織服裝及鞋包、嬰童玩具及家居生活、電子電器、醫(yī)學(xué)健康、食品及農(nóng)產(chǎn)品……等行業(yè)的供應(yīng)鏈上下游。
特色服務(wù)

全面保障品質(zhì)與安全，推動(dòng)合規(guī)與創(chuàng)新，彰顯品牌競(jìng)爭(zhēng)力，實(shí)現(xiàn)更高質(zhì)量、更健康、更安全、更綠色的可持續(xù)發(fā)展。
新聞資訊

黎明前的黑暗——MET 抑制劑的失敗案例

發(fā)布時(shí)間：2020-11-09 瀏覽次數(shù)：1449
作者：腫瘤時(shí)間 抗體圈
參考文獻(xiàn)

1. De Silva DM, et al. Targeting the hepatocyte growth factor/Met pathway in cancer. Biochem Soc Trans. 2017;45(4):855-70.

2. Liang H, Wang M. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. Onco Targets Ther. 2020 Mar 25;13:2491-2510.

3. Spigel DR, et al. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. J Clin Oncol. 2017;35(4):412-420.

4. Shah MA, et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncol. 2017;3(5):620-627.

5. Scagliotti G, et al. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients. J Thorac Oncol. 2020;15(1):80-90.

6. Scagliotti G, et al. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33(24):2667-74.

7. Yoshioka H, et al. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Ann Oncol. 2015;26(10):2066-72.

8. Giorgio V. Scagliotti, et al. Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. J Thorac Oncol. 2017;13(6):849-854.

9. Bylicki O, et al. Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date. Onco Targets Ther. 2020;135691-5706.

10. Awad MM, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96-102.